323 results on '"Villemagne V"'
Search Results
2. Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden
Catalog
Books, media, physical & digital resources
3. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study
4. Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
5. F-18-PI-2620 3R Pick Tau PET Imaging in Frontotemporal Lobar Degeneration (FTLD)
6. A[Beta] Deposits in Older Non-Demented Individuals with Cognitive Decline Are Indicative of Preclinical Alzheimer's Disease
7. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment
8. Tau deposition patterns are associated with functional connectivity in primary tauopathies
9. Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy
10. A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study
11. Combining 18F-florbetaben Aβ imaging and MRI in mild cognitive impairment: OR38
12. Cerebrovascular disease, Alzheimerʼs disease biomarkers and longitudinal cognitive decline: OR2
13. Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden.
14. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimerʼs disease
15. Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease
16. Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing
17. HIGHER AB BURDEN IN HEALTHY APOE-E4 CARRIERS IS ASSOCIATED WITH SUBJECTIVE MEMORY COMPLAINTS: RESULTS FROM THE FLUTEMETAMOL AND PIB AIBL COHORTS: O40
18. DETECTION OF PRODROMAL ALZHEIMERʼS DISEASE WITH 18F-FLORBETABEN IMAGING: A PROSPECTIVE OUTCOME STUDY: O37
19. Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET
20. 18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy.
21. Chronic stress and Alzheimer's disease: the interplay between the hypothalamic-pituitary-adrenal axis, genetics and microglia
22. Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET
23. RP25- Sigmoid methodology allows early prediction of cognitive decline towards Alzheimer's disease across several cognitive domains
24. MilxXplore: a web-based system to explore large imaging datasets
25. Midlife vascular risk and late-life Alzheimerʼs disease: data from the Womenʼs Healthy Ageing Project (WHAP)
26. Cerebral microbleeds, brain β-amyloid and clinical trajectories: results from the AIBL study of ageing
27. Blood and imaging biomarkers of neurodegeneration: S09-3
28. IMAGING AND COGNITIVE BIOMARKERS AS PREDICTORS OF PROGRESSION TO ALZHEIMERʼS DISEASE: O38
29. A TWO-YEAR LONGITUDINAL ASSESSMENT OF Aβ DEPOSITION IN MCI WITH 18F-FLORBETABEN: O35
30. Incidence and associations of lobar microbleeds: Results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL): S14 Session 14: Oral Presentations 3 May 2012 1415-1430 Oral Presentation 27
31. Correlating the frontal presentation of Alzheimerʼs disease with frontal metabolism as measured by FDG-PET: S14 Session 14: Oral Presentations 3 May 2012 1400-1415 Oral Presentation 32
32. Binding characteristics of 18 F-PI-2620 differentiate the clinically predicted tau isoform in suspected 3/4-repeat and 4-repeat tauopathies
33. As a (white) matter of fact – Different white matter properties of beta-amyloid PET tracers
34. 18 F-PI2620 Tau-PET in Progressive Supranuclear Palsy – A Multi-Center Evaluation
35. Perfusion-Phase 18 F-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neuronal Injury
36. 18 F-PI2620 Tau-PET for Assessment of Heterogeneous Neuropathology in Corticobasal Syndrome
37. 11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease
38. MOLECULAR IMAGING STUDIES AS BIOMARKERS OF NEURODEGENERATION: S21-03
39. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
40. Relationship between nicotinic receptors and cognitive function in early Alzheimerʼs disease: A 2-[18F]fluoro-A-85380 PET study
41. CEREBRAL AMYLOID ANGIOPATHY PREDISPOSES TO TPA RELATED HAEMORRHAGE IN PATIENTS PRESENTING WITH ACUTE ISCHAEMIC STROKE: A PIB PET STUDY: 1
42. IN VIVO DETECTION OF CEREBRAL AMYLOID DEPOSITION USING 11C PIB PET IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY HAEMORRHAGE: 2
43. DETECTION OF CEREBRAL AMYLOID DEPOSITION USING [11C]PIB PET IN PATIENTS WITH PROBABLE CEREBRAL AMYLOID ANGIOPATHY
44. F-18-PI-2620 Tau-PET in Corticobasal Syndrome
45. [18F]PI-2620 Tau PET to Improve Imaging-Based Diagnosis of PSP
46. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
47. Dopamine Transporter Changes in Neuropsychiatric Disorders
48. Application of the NIA-AA research framework: Towards a biological definition of Alzheimer’s disease using cerebrospinal fluid biomarkers in the AIBL study
49. Engineered antibodies: new possibilities for brain PET?
50. Klotho allele status is not associated with Aß and APOE e4–related cognitive decline in preclinical Alzheimer's disease
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.